Company newsCompany release
Pfizer PFE
Pfizer and Blackstone Life Sciences announce co-funding deal for obesity drug
Pfizer said funds managed by Blackstone will pay up to $1.5 billion of development costs through 2028 for berobenatide.
GetSignal
Free on iOS and Android
Pfizer and Blackstone Life Sciences announced on November 11, 2026, a strategic co-funding agreement for berobenatide, an investigational monthly GLP-1 receptor agonist peptide.
The drug is being studied for chronic weight management and obesity-related conditions.
Key facts
- Maximum funding
- Up to $1.5 billion
- Funding period
- Through 2028
- Drug
- Berobenatide, an investigational monthly GLP-1 receptor agonist peptide
- Partner
- Blackstone Life Sciences
Source: The company's release on Business Wire, November 11, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
More company news
Pfizer first, then the newest- Florida Power & Light doubles Saving Steps funding to $30 million
NEE · NextEra Energy · Company release ·